Federally Funded Clinical Trials
Our research sites continue to participate in Federally-funded research through NRG Oncology. The following protocols are currently open to accrual. Please visit the NRG Oncology website or the CTSU members' website for more information.
NSABP B-51
Protocol Activation (Date Opened to Accrual): 08/22/2013
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
ClinicalTrials.gov Identifier: NCT01872975
NRG - BR003
Protocol Activation (Date Opened to Accrual): 06/26/2015
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
ClinicalTrials.gov Identifier: NCT02488967
NRG - BR004
Protocol Activation (Date Opened to Accrual): 03/12/2019
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT03199885
NRG - BR005
Protocol Activation (Date Opened to Accrual): 04/13/2017
A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients With Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery
NRG - GI002
Protocol Activation (Date Opened to Accrual): 10/12/2016
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
ClinicalTrials.gov Identifier: NCT02921256
NRG - GI004
Protocol Activation (Date Opened to Accrual): 11/7/17
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
ClinicalTrials.gov Identifier: NCT02997228